NASDAQ · LGVN
Longeveron Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for LGVN: Nov 3, 2026
Longeveron Inc. Class A Common Stock is estimated to report earnings on 11/03/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.7. The reported EPS for the same quarter last year was $-3.9.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.70 | $-1.70 | $-1.70 | 1 |
| Dec 2026 | $-1.70 | $-1.70 | $-1.70 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · The Motley Fool- RTTNews · Oct 27, 10:28 AM EDTLongeveron Reports Fewer Cardiac Events In Phase 2b Heart Syndrome Trial After Primary Endpoint Miss(RTTNews) – Longeveron Inc. (LGVN), a clinical-stage biotechnology company, said Monday that an updated analysis of its Phase 2b ELPIS II trial showed significantly fewer major adverse cardiac events with laromestrocel, meeting a prespecified secondary endpoint after the trial mi
- RTTNews · Sep 18, 10:44 AM EDTWeekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead(RTTNews) – Biotech investors tracked a busy week marked by regulatory approvals, strategic collaborations, workforce restructuring and key clinical trial readouts.
- RTTNews · Sep 16, 10:31 PM EDTLongeveron's Laromestrocel Misses Primary Endpoint In Phase 2b HLHS Trial; Stock Down 59%(RTTNews) – Longeveron (LGVN) reported topline results from the Phase 2b ELPIS II trial of laromestrocel in infants with hypoplastic left heart syndrome, with the study failing to meet its primary endpoint of improving right ventricular ejection fraction at 12 months.
- RTTNews · Aug 25, 2:59 AM EDTLongeveron To Enter 1-for-10 Reverse Stock Split For Minimum Bid Price Compliance; Shares Plunge(RTTNews) – Longeveron Inc. (LGVN), a clinical-stage biotechnology company developing cellular therapy, announced a 1-for-10 reverse split of the company's Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share.
- RTTNews · Aug 19, 9:16 PM EDTLongeveron Appoints Jhaveri As CFO Ahead Of Phase 2b Data; Stock Up(RTTNews) – Longeveron Inc. (LGVN), a clinical-stage biotech company focused on developing cellular therapies for rare paediatric and chronic age-related diseases, on Wednesday announced the appointment of Nirav Jhaveri as Chief Financial Officer (CFO).
- The Motley Fool · Aug 19, 5:58 PM EDTLongeveron (LGVN) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Jul 7, 1:57 AM EDTLongeveron CFO Lisa Locklear To Step Down; Marie Washburn Appointed As Successor(RTTNews) – Longeveron Inc. (LGVN) on Monday announced that Chief Financial Officer Lisa Locklear is stepping down to pursue board opportunities and other professional and personal interests. The company appointed Marie Washburn as Senior Vice President and CFO, effective July 13
- The Motley Fool · May 13, 6:06 PM EDTLongeveron (LGVN) Q1 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · May 11, 4:24 AM EDTLongeveron Holds Constructive FDA Meeting; ELPIS II Topline Data Expected August 2026(RTTNews) – Longeveron Inc. (LGVN) on Friday announced it held a constructive Type C meeting with the U.S. FDA regarding its ongoing Phase 2b ELPIS II trial of laromestrocel (Lomecel-B) in hypoplastic left heart syndrome (HLHS).
- RTTNews · Mar 18, 10:27 AM EDTLongeveron To Report Phase 2b ELPIS II Trial Data For Lomecel-B In Q3 2026(RTTNews) – Longeveron Inc. (LGVN), a clinical-stage biotechnology company, reported financial results for the year ended December 31, 2025, and provided an update on its lead investigational product, Laromestrocel (LOMECEL-B).
- The Motley Fool · Mar 18, 9:34 AM EDTLongeveron (LGVN) Q4 2025 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Mar 10, 10:47 AM EDTLongeveron Shares Soar 87% Over $30 Mln Private Placement Announcement(RTTNews) – Shares of Longeveron Inc. (LGVN) are surging about 87 percent on Tuesday morning trading following the announcement of a definitive agreement with certain institutional and accredited investors for a private placement of upto approximately $30 million.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Longeveron Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.